Related Experiment Videos
Soluble CD16 in plasma cell dyscrasias.
C Mathiot1, J Galon, E Tartour
1Hématologie biologique, INSERM U255, Institut Curie, Paris, France. cmathiot@hol.fr
Leukemia & Lymphoma
|February 27, 1999
Summary
Soluble CD16 (sCD16) levels in serum are significantly lower in multiple myeloma and progressing MGUS patients. This finding highlights the prognostic value of sCD16 in monoclonal gammopathies.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Soluble Fc gamma receptor type III (sFcγRIII or sCD16) is found in biological fluids, primarily binding IgG complexes.
- In plasma, sCD16 originates from the cleavage of membrane-bound CD16 on neutrophils and NK cells.
Purpose of the Study:
- To investigate the prognostic value of serum sCD16 levels in monoclonal gammopathies.
- To explore the biological significance of sCD16 level alterations in these conditions.
Main Methods:
- Serum sCD16 levels were determined in patients with monoclonal gammopathies, including multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS).
- Comparison of sCD16 levels was made between different MGUS subtypes (progressing vs. stable) and healthy controls.
Main Results:
- Markedly reduced serum sCD16 levels were observed in multiple myeloma patients.
- Significantly lower sCD16 levels were found in MGUS patients who rapidly progressed to multiple myeloma compared to those with stable MGUS or controls.
- These findings indicate a prognostic value for serum sCD16 levels.
Conclusions:
- Serum sCD16 levels serve as a valuable prognostic biomarker in monoclonal gammopathies.
- Monitoring sCD16 levels can aid in identifying MGUS patients at higher risk of progression to multiple myeloma.